Optimizing teicoplanin dosing for bacterial infections
A Randomized Trial Investigating the Superiority of TDM-optimized Teicoplanin Dosing Versus Standard of Care
This study is testing if a new way of dosing the antibiotic teicoplanin can help patients with bacterial infections in intensive care get better treatment compared to the usual dosing methods.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 74 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Radboud University Medical Center Academic / other |
| Locations | 1 site (Nijmegen) |
| Trial ID | NCT05914467 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of therapeutic drug monitoring (TDM) for teicoplanin, a glycopeptide antibiotic, compared to standard dosing guidelines. Conducted at a single center, the study aims to determine if Model-Informed-Precision-Dosing (MIPD) of unbound teicoplanin concentrations can achieve better target attainment in patients with bacterial infections. The trial focuses on patients in intensive care and specific departments, aiming to enhance treatment safety and efficacy while minimizing resistance development.
Who should consider this trial
Good fit: Ideal candidates include adult patients admitted to the ICU or specific departments who are being treated with teicoplanin.
Not a fit: Patients who are pregnant or have a short expected duration of teicoplanin therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and safer antibiotic treatment for patients with bacterial infections.
How similar studies have performed: While the use of TDM for vancomycin has shown success, the application of TDM for teicoplanin is less established, making this study a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. The patient is admitted to the ICU, haematology, gastroenterology or orthopaedics department. 2. The patient is at least 18 years old on the day of inclusion. 3. The patient is treated with teicoplanin as part of standard care. 4. The patient or a representative is willing to sign the Informed Consent Form Exclusion Criteria: 1. The patient has previously participated in this study. 2. The patient receives any form of renal replacement criteria (RRT) other than CVVHD / CVVHDF. 3. Expected duration of teicoplanin therapy is less than 5 days. 4. The patient is pregnant
Where this trial is running
Nijmegen
- RadboudUMC — Nijmegen, Netherlands (Recruiting)
Study contacts
- Principal investigator: Nynke Jager — Radboud university medical center (Radboudumc)
- Study coordinator: jaap Mouton
- Email: jaap.mouton@radboudumc.nl
- Phone: 0031 24 361 9191
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.